Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study - Wikidata - wikimedia - TriplyDB

Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study

Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study

http://www.wikidata.org/entity/Q35114460

about

Vascular endothelial growth factor inhibitors: investigational therapies for the treatment of psoriasis New perspectives in glioblastoma antiangiogenic therapy The Role of a Single Angiogenesis Inhibitor in the Treatment of Recurrent Glioblastoma Multiforme: A Meta-Analysis and Systematic Review Recurrent Glioblastoma: Where we stand Nonsurgical treatment of recurrent glioblastoma Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date Twisted tango: brain tumor neurovascular interactions Mechanisms of evasive resistance to anti-VEGF therapy in glioblastoma Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites?Adaptation to antiangiogenic therapy in neurological tumors Postoperative deterioration in health related quality of life as predictor for survival in patients with glioblastoma: a prospective study Angiogenic inhibition in high-grade gliomas: past, present and future.Response assessment criteria for glioblastoma: practical adaptation and implementation in clinical trials of antiangiogenic therapy.Bifunctional chelates optimized for molecular MRI Diagnostic performance between contrast enhancement, proton MR spectroscopy, and amide proton transfer imaging in patients with brain tumors.Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas.MRI biomarkers identify the differential response of glioblastoma multiforme to anti-angiogenic therapy.Medical therapy of gliomas.Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD).Incidence and risk of proteinuria with aflibercept in cancer patients: a meta-analysis.Antiangiogenic therapy for glioblastoma: current status and future prospects.The future of high-grade glioma: Where we are and where are we going.The challenges and the promise of molecular targeted therapy in malignant gliomas.Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma.The effect of anti-VEGF drugs (bevacizumab and aflibercept) on the survival of patients with metastatic colorectal cancer (mCRC)Clinical benefit from resection of recurrent glioblastomas: results of a multicenter study including 503 patients with recurrent glioblastomas undergoing surgical resection.Improved Treatment Efficacy of Antiangiogenic Therapy when Combined with Picornavirus Vaccination in the GL261 Glioma Model.Standards of care for treatment of recurrent glioblastoma--are we there yet?Current status and future directions of anti-angiogenic therapy for gliomas Cytokines associated with toxicity in the treatment of recurrent glioblastoma with aflibercept A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients.Bevacizumab for glioblastoma: current indications, surgical implications, and future directions Development of a preclinical PK/PD model to assess antitumor response of a sequential aflibercept and doxorubicin-dosing strategy in acute myeloid leukemia Antiangiogenic and Antitumor Activities of Aflibercept, a Soluble VEGF Receptor-1 and -2, in a Mouse Model of Hepatocellular Carcinoma.Drug Monographs: Ziv-aflibercept and Vincristine Sulfate Liposome.Standards of care and novel approaches in the management of glioblastoma multiforme.A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer.Investigational VEGF antagonists for psoriasis.Is there a world beyond bevacizumab in targeting angiogenesis in glioblastoma?Antiangiogenic therapies in glioblastoma multiforme.

P2860

Q22305863-F6126619-8701-42E7-A7A2-45E9F17250D9 Q26746028-184FB8FE-EC1E-4BAD-AAB1-4933AC00C43D Q26752321-D01D7594-E49A-4157-ABBD-33B6B5006479 Q26765042-A15793E0-B311-4715-930B-27C3A18FB96B Q26795560-E45EDA13-C01B-4DBB-B318-5528031750B0 Q26822717-58AB8826-2B93-4239-BE2A-137021466C73 Q26849613-75FA6A80-1CB9-4378-828D-D8B39DEA75E2 Q27021470-B2467275-2E1D-418D-8CC3-FF24455ACA98 Q28078539-54646D80-B982-45D3-953B-1A92E19AB51A Q28082908-62DE6C6E-BA60-48F3-8F38-B32C4552D55D Q28741648-BF800F9C-F37F-429C-88F0-D2C74FF75803 Q30455596-5BFD9356-C185-4A6B-9240-C68AD4A58849 Q30607148-7D78A664-F525-475C-8A8B-1742422500FC Q30831437-B106BCA8-BD2E-40EF-A86F-E40A6FB3C1B0 Q31169659-9F330DB0-A911-43BD-96EA-86A88EFEE87E Q33438666-A3004644-B114-4736-997E-E4DE5BD3D63D Q33616649-3D7E1974-4A86-4F64-844E-7CE7880433F6 Q34218761-C8E2E479-0A5D-4198-8CB7-0E524E132B04 Q34331320-DB50B557-F74E-4C38-A03D-A7A6D0A0539B Q34445829-4A6A217F-2BC9-41E6-98CC-54720F45D56C Q34523319-B13A302B-B04D-4B60-ADFF-D33811E5F664 Q35114090-91795C5E-6046-4629-8973-81C13E2A8F55 Q35214534-1C0ED4D8-D946-41F2-B33B-5A33582C6AE1 Q35895174-1E33DE72-9E72-4923-B2CC-5863D77461CB Q35938926-9E65FDA8-87A9-41D1-B6E7-E35A0040979C Q36367414-8CC6B98C-04C2-4ADE-A587-683DECA46766 Q36484434-2B4C393C-ECE2-4EDC-B657-FDE4221DCFB8 Q36500401-3293FAD9-01B6-4F78-8D4F-E03D8AE5B2F0 Q36618235-4CD609B5-D5E8-4F75-89A2-272A5F03B9EB Q36712746-39825CDE-02A7-4AD2-8587-2524B57B8540 Q36782767-4D4264AB-5366-45E0-A198-7DA27E9F70D5 Q36822207-BEF37C3D-8EF3-4B3B-A078-3814E841F78A Q36951941-1B4F4E4D-199F-4F20-B4C7-B9BD03FFA8E8 Q37112714-D0DEE203-39C2-4B04-AE34-915538A1C793 Q37339929-B3728ADA-1224-41E9-AABE-B4C0E0079278 Q37525881-EE54F700-1DAB-4B75-BDB2-9C22A0E542D8 Q37558971-ED885C7D-BFBB-4957-9485-F574991ED4AA Q37956733-F3F36AAE-6DE8-471C-AD40-03174E92B516 Q37993124-21C671D4-EE37-4273-9239-D39E6EA7B018 Q38010802-8C84D95C-76AB-4FDC-BC01-EF6769FCD36B

P2860

Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study

http://www.wikidata.org/entity/Q35114460

description

2011 nî lūn-bûn

@nan

2011 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Phase II study of aflibercept ...... n Brain Tumor Consortium study

@ast

Phase II study of aflibercept ...... n Brain Tumor Consortium study

@en

type

label

Phase II study of aflibercept ...... n Brain Tumor Consortium study

@ast

Phase II study of aflibercept ...... n Brain Tumor Consortium study

@en

prefLabel

Phase II study of aflibercept ...... n Brain Tumor Consortium study

@ast

Phase II study of aflibercept ...... n Brain Tumor Consortium study

@en

P1433

Q35114460-7153121A-6AC6-4732-81DD-D4072B733926

P1476

Q35114460-1272E291-BF42-4CD4-97BC-F2F5BA0BEB73

P2093

Q35114460-0BC4A7BE-CFDB-4A1E-A715-E8C3E3DA5600

Q35114460-33218A4F-6B55-4CF2-BB8F-A79C7BE5DD40

Q35114460-54D6D016-8A18-4581-8B70-A561465B4964

Q35114460-5ABB4E48-16D4-4181-A10B-3C49D0E963B3

Q35114460-6004796C-1FC0-44A8-BA24-B9B760D0E3EA

Q35114460-63D25DF7-30CF-4B55-AFB8-0D38F6EB3627

Q35114460-6545A0E6-4882-4A4E-92C4-1D3DC416722D

Q35114460-7BD6DF80-24A8-46CE-A334-BCBF3C33CD12

Q35114460-98610360-FE74-4153-BF74-8E678C67EA90

Q35114460-9D3DF945-BB96-4D50-8349-260EA242C6E7

P2860

Q35114460-04539BC0-272F-4336-8E05-08BC6D4C89E0

Q35114460-168D063E-E8B9-49B9-BE59-C2EFF50851F5

Q35114460-1CF17E0E-5F11-4429-9EC6-75F2D83AA90E

Q35114460-2145B6F1-9B58-44C7-AD48-D9CA0C2A147E

Q35114460-256ADF49-7A54-4F71-9822-5AF125422A56

Q35114460-2FBC9B4F-962C-4C33-9878-8F1BB33870DF

Q35114460-370C2C0F-AB1E-41C0-A16E-7B1E5B6B4A4C

Q35114460-3DB99899-D21C-4A9F-9C0E-287BA5785DBB

Q35114460-49347FCB-4149-4721-A926-E4DBBE293C2E

Q35114460-4A03795A-AC64-4FFD-9CC6-ADDF28079A67

P304

Q35114460-A9891F90-0F2B-490A-88C8-2164F723F5DC

P31

Q35114460-BD136D08-DA98-4A99-AB55-79208983CB54

P356

Q35114460-7B2DDFCF-F37C-42CF-96C8-AA632772EC6E

P407

Q35114460-1B48E866-5CE1-47CF-B80F-FACD3CB474A9

P433

Q35114460-21885400-E6BD-4554-8D70-F9C4ECFC9489

P478

Q35114460-EF90E05D-7514-4D60-AEC8-0AF2CB06A34A

P50

Q35114460-5B076972-062D-441A-B89D-D43843492A12

Q35114460-930B0539-6A47-493D-A502-B5CFB4D5B9A8

Q35114460-CDF7FD11-7BE3-49FC-8614-1FD7CD79986B

P577

Q35114460-1FD251A3-0BF4-494A-9719-90E04CDCBAF1

P698

Q35114460-29DBD64C-ADE2-4E27-979D-67D4A34C8EC0

P932

Q35114460-B820BCE1-3A1C-4FF9-8B7E-B203A6AB953B

P356

JCO.2010.34.1636

P1433

Journal of Clinical Oncology

P1476

Phase II study of aflibercept ...... n Brain Tumor Consortium study

@en

P2093

Alice Chen

http://www.w3.org/2001/XMLSchema#string

Andrew B Lassman

http://www.w3.org/2001/XMLSchema#string

Frank Lieberman

http://www.w3.org/2001/XMLSchema#string

H Ian Robins

http://www.w3.org/2001/XMLSchema#string

John F de Groot

http://www.w3.org/2001/XMLSchema#string

Jun Yao

http://www.w3.org/2001/XMLSchema#string

Kathleen R Lamborn

http://www.w3.org/2001/XMLSchema#string

Kenneth Aldape

http://www.w3.org/2001/XMLSchema#string

Mark R Gilbert

http://www.w3.org/2001/XMLSchema#string

Michael D Prados

http://www.w3.org/2001/XMLSchema#string

P2860

Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels

Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

The role of myeloid cells in the promotion of tumour angiogenesis

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

Whole-genome gene expression profiling of formalin-fixed, paraffin-embedded tissue samples.

A versatile assay for high-throughput gene expression profiling on universal array matrices

Empirical Bayes accomodation of batch-effects in microarray data using identical replicate reference samples: application to RNA expression profiling of blood from Duchenne muscular dystrophy patients.

P304

2689-2695

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2010.34.1636

http://www.w3.org/2001/XMLSchema#string

P407

P433

19

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P50

Edward F. Jackson

Lisa M DeAngelis

P577

2011-05-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21606416

http://www.w3.org/2001/XMLSchema#string

P932

3139373

http://www.w3.org/2001/XMLSchema#string